PRESS & MEDIA
LYEONS focuses on advancing brain health through innovative solutions in neuroprotection and sensory modulation. The company works to support individuals affected by stress, anxiety, and trauma by developing tools that may help regulate the autonomic nervous system. Our commitment to scientific research and collaboration is reflected in various media coverage, where stories highlight our technology and the progress we’re making in early intervention and long-term well-being.
The latest wave of value creators to emerge from Babraham Research Campus’ Accelerate@Babraham accelerator used skills honed as part of the eight-week taught element of the programme to pitch to stakeholders and investors.
Neurotechnology can, at least in part, help fill the gap before symptoms get worse. There are a number of startup companies in the anxiety space, working on both hardware and software for anxiety management.
Cambridge NeuroWorks Fellows had a brilliant opportunity to showcase their research at the Cambridge NeuroWorks Connecting Neuroscience event, held in collaboration with Cambridge Neuroscience and Cambridge Network.
Meet Lucy Jung – Frontier Fellow at Cambridge NeuroWorks. Her journey began with a drive to improve quality of life for people living with long-term conditions. After completing degrees in Industrial Design in Korea and Innovation Design Engineering in London, she turned her focus to neuromodulation, creating solutions that interface directly to the body’s nervous system.
Innovation in healthcare begins by deeply understanding user and key stakeholders needs to develop solutions that truly fit into real-world contexts. By aligning these insights with robust scientific research, we can ensure medical technologies are both evidence-based and deliver clear value, driving meaningful and sustainable impact.
With its university spires and world-leading science sector, many believe life in Cambridge is one of privilege and wealth, but it is one of the most unequal cities, external in the UK.
LYEONS named in the final #21toWatch for 2025, recognising innovation and impact in Cambridge and the East of England. This campaign celebrates emerging talent across all sectors, showcasing those shaping the future of entrepreneurship.
Cambridge ranks 3rd globally as a science and technology hub, following Silicon Valley and Boston. But innovation thrives on people. LYEONS founder has been shortlisted for the #21toWatch list, recognising individuals driving change.
LYEONS joins Cambridge Judge Business School, leveraging its research and entrepreneurial ecosystem to advance innovation in neurotechnology. Through this collaborationhum, the company refines its approach to brain health solutions,
MedTech entrepreneur Lucy Jung (MSc Innovation Design Engineering 2019), founder of Charco Neurotech and LYEONS, is among this year’s honourees. Recognised for her impact in neurotechnology.